Human protozoan infections are an important target for development of new vaccines and drugs. No completely efficacious vaccines for human protozoan infections are available and in the case of malaria resistance to the most efficacious antimalarials has become a global challenge. In ocular toxoplasmosis complete eradication of the body is not possible, exposing patients to new reactivations.

The need of treatment or vaccines for Cryptosporidium and of less toxic drugs for Leishmania are urgent tasks for protozoologists research community. New research strategies have appeared that enlarged the possibilities for treatment and vaccine development. Reverse vaccinology, bioinformatic search of second use drug candidates and ex vivo analysis have afforded new fields for development. This Research Topic will look to examine these new possibilities, will bring together specialists and experiences that will feed the next wave of drugs and vaccines for this group of infections that have large consequences for human beings.

This Research Topic welcomes original contributions in the field of immunoinformatics, second use of drugs analysis and the in vivo and in vitro evaluation of new compounds against protozoa. Original contributions about second use compounds for protozoan diseases, application of immunoinformatics to identify new vaccine candidates and of chimioinformatics for the development of new drugs against theses parasitic diseases are of particular interest to be included in this project. Invited reviews from experts in the field will analyze the current developments and the critical points that still to be surmounted into the quest for efficacious and non toxic compounds and vaccines to be used in animal and human for theses diseases.

How we work:

  • After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
  • A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
  • Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.

Media Contact:
Stella M
Journal Manager
Immunome Research